Amirali Talasaz Sells 143,028 Shares of Guardant Health (NASDAQ:GH) Stock

Guardant Health, Inc. (NASDAQ:GH) CEO Amirali Talasaz sold 143,028 shares of the firm’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $151.54, for a total transaction of $21,674,463.12. Following the completion of the sale, the chief executive officer owned 1,881,336 shares in the company, valued at $285,097,657.44. This represents a 7.07% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Amirali Talasaz also recently made the following trade(s):

• On Friday, June 26th, Amirali Talasaz sold 116,972 shares of Guardant Health stock. The shares were sold at an average price of $150.79, for a total transaction of $17,638,207.88.
• On Wednesday, May 20th, Amirali Talasaz sold 210,000 shares of Guardant Health stock. The shares were sold at an average price of $109.89, for a total value of $23,076,900.00.
• On Tuesday, May 12th, Amirali Talasaz sold 50,000 shares of Guardant Health stock. The stock was sold at an average price of $100.32, for a total value of $5,016,000.00.

Guardant Health Price Performance

Shares of GH traded down $3.71 during trading hours on Tuesday, hitting $150.03. The stock had a trading volume of 3,327,903 shares, compared to its average volume of 2,298,095. The firm has a market capitalization of $19.89 billion, a PE ratio of -44.26 and a beta of 1.61. Guardant Health, Inc. has a 12 month low of $40.35 and a 12 month high of $153.95. The stock has a fifty day moving average price of $113.99 and a 200 day moving average price of $104.38.

Analyst Ratings Changes

Several research firms have recently commented on GH. Barclays upped their price target on shares of Guardant Health from $120.00 to $150.00 and gave the company an “overweight” rating in a research report on Wednesday, June 24th. Mizuho raised their price objective on shares of Guardant Health from $135.00 to $175.00 and gave the stock an “outperform” rating in a report on Monday, June 8th. Guggenheim boosted their target price on shares of Guardant Health from $135.00 to $160.00 and gave the company a “buy” rating in a research report on Monday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Guardant Health in a report on Tuesday, April 21st. Finally, Piper Sandler set a $127.00 price target on shares of Guardant Health in a research report on Thursday, May 21st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Guardant Health presently has a consensus rating of “Buy” and a consensus price target of $144.82.

Institutional Investors Weigh In On Guardant Health

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Hamilton Wealth LLC raised its stake in Guardant Health by 103.0% during the 1st quarter. Hamilton Wealth LLC now owns 76,700 shares of the company’s stock worth $7,085,000 after acquiring an additional 38,916 shares during the period. Western Wealth Management LLC bought a new position in shares of Guardant Health in the first quarter worth approximately $125,000. Perceptive Advisors LLC boosted its position in shares of Guardant Health by 87.5% in the first quarter. Perceptive Advisors LLC now owns 300,000 shares of the company’s stock worth $27,711,000 after purchasing an additional 140,000 shares during the period. BankChampaign National Association purchased a new stake in shares of Guardant Health in the first quarter worth $809,000. Finally, Edgestream Partners L.P. raised its position in shares of Guardant Health by 321.6% during the 1st quarter. Edgestream Partners L.P. now owns 32,257 shares of the company’s stock valued at $2,980,000 after purchasing an additional 24,606 shares during the period. 92.60% of the stock is owned by hedge funds and other institutional investors.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.